These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15034838)

  • 1. Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome.
    Chen XP; Cao Y
    Clin Infect Dis; 2004 Apr; 38(7):1030-2. PubMed ID: 15034838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.
    Guest JL; Ruffin C; Tschampa JM; DeSilva KE; Rimland D
    Pharmacotherapy; 2004 Jun; 24(6):727-35. PubMed ID: 15222662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
    Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M;
    AIDS; 2008 Jan; 22(2):F1-9. PubMed ID: 18097218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
    Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
    J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection.
    Kaplan SS; Hicks CB
    J Antimicrob Chemother; 2005 Aug; 56(2):273-6. PubMed ID: 15994247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine.
    Manavi K; McDonald A; Al-Sharqui A
    AIDS; 2007 Mar; 21(5):643-5. PubMed ID: 17314527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
    Moltó J; Santos JR; Negredo E; Miranda C; Videla S; Clotet B
    J Antimicrob Chemother; 2007 Aug; 60(2):436-9. PubMed ID: 17556354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.
    Crommentuyn KM; Mulder JW; Sparidans RW; Huitema AD; Schellens JH; Beijnen JH
    Clin Infect Dis; 2004 Apr; 38(8):e73-5. PubMed ID: 15095234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation.
    Meraviglia P; Schiavini M; Castagna A; Viganò P; Bini T; Landonio S; Danise A; Moioli MC; Angeli E; Bongiovanni M; Hasson H; Duca P; Cargnel A
    HIV Med; 2004 Sep; 5(5):334-43. PubMed ID: 15369508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of lopinavir/ritonavir for the treatment of HIV-infection.
    Vogel M; Rockstroh JK
    Expert Opin Drug Saf; 2005 May; 4(3):403-20. PubMed ID: 15934849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low prevalence of subclinical severe acute respiratory syndrome-associated coronavirus infection among hospital healthcare workers in Hong Kong.
    Lai TS; Keung Ng T; Seto WH; Yam L; Law KI; Chan J
    Scand J Infect Dis; 2005; 37(6-7):500-3. PubMed ID: 16012012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
    J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.